May Case of the Month
Clinical History:A 57-year-old woman with stage IV lung adenocarcinoma (Figure 1) with an EGFR L858R mutation was treated with erlotinib (an EGFR tyrosine kinase inhibitor). After initial response to treatment for over 1 year, she developed extensive metastatic disease at the T5 vertebra (biopsy shown in Figure 2). By immunohistochemistry, the tumor labeled for CAM 5.2, TTF-1, synaptophysin, and chromogranin A (Figure 3). The Ki-67 (MIB-1) labeling index was over 70% (Figure 4).
Click here to see more.
ASCP - Update in Pulmonary Pathology: Contemporary Classification & Diagnosis
Dr. Andrew Churg, Director
May 10 - 12, 2018
Chicago, IL
Co-sponsored by PPS
Thoracic Pathology Update
Drs. Mari Mino-Kenudson & WilliamTravis, Co-directors
June 22 - 24, 2018, 2018
Massachussets General Hospital Boston, MA
Co-sponsored by PPS
International Academy of Pathology Meeting (IAP)
October 14-18, 2018
Dead Sea NR, Amman, Jordan
Pulmonary Pathology Society
Biennial Meeting
June 26-June 28, 2019
Dubrovnik, Croatia
